Shivanthan Shanthikumar

Jul 1, 2024 | medrxiv.org | Shivanthan Shanthikumar |Liam Gubbels |Karen Davies |Hannah Walker

The authors have declared no competing interest. This work was funded by Chan Zuckerberg Initiative Single-Cell Biology Grants (2021-237883, 2020-217531). We thank the children and parents who participated in our studies, without whom this work would not exist. I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.

May 9, 2024 | medrxiv.org | Shivanthan Shanthikumar |Karen Davies |Hannah Walker |Liam Gubbels

The authors have declared no competing interest. This work was funded by a Chan Zuckerberg Initiative Single-Cell Biology Grant (2021-237883). I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.

Mar 19, 2024 | onlinelibrary.wiley.com | Shivanthan Shanthikumar |Nusrat Homaira |Brett Montgomery |Harriet Hiscock

To the editor, The Australian Institute of Health and Welfare (AIHW) recently released a report regarding Asthma in Australia, including trends over the past 5 years, and pediatric-specific data.1 It used national data sets to assess prevalence, disease burden, and the state of asthma care against a set of predetermined “National Asthma Indicators.” Unfortunately, the report highlights several worrying results regarding pediatric asthma in Australia.

Apr 17, 2023 | thelimbic.com | Brett Montgomery |Louisa Owens |Shivanthan Shanthikumar

Last week, without warning, the federal government significantly restricted the subsidy for an important and safe asthma medicine for children. A short document explained to prescribers what had changed, but gave no reasons. The medicine, fluticasone propionate 50mcg, is a metered-dose inhaler, more commonly known by the brand names Flixotide Junior or Axotide Junior.

Apr 12, 2023 | medicalxpress.com | Brett Montgomery |Louisa Owens |Shivanthan Shanthikumar

Last week, without warning, the federal government significantly restricted the subsidy for an important and safe asthma medicine for children. A short document explained to prescribers what had changed, but gave no reasons. The medicine, fluticasone propionate 50mcg, is a metered-dose inhaler, more commonly known by the brand names Flixotide Junior or Axotide Junior.